Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | DTYMK | P23919 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29771020 | 0.82 | KDM1A (0.38) | POLBGPR119KDM1AMAPK1FNTA | |
| SCHEMBL2109651 | 0.80 | RBP4 (0.51) | KDM1AMAPK1ALOX15TSHRUSP30 | |
| SCHEMBL12566957 | 0.80 | POLB (0.49) | POLBGPR119OPRD1OPRK1MAPK1 | |
| SCHEMBL31694131 | 0.80 | POLB (0.49) | POLBGPR119OPRD1OPRK1DTYMK | |
| SCHEMBL20510139 | 0.79 | POLB (0.48) | POLBGPR119OPRD1OPRK1KDM1A | |
| SCHEMBL12701629 | 0.79 | AVPR1A (0.50) | POLBGPR119OPRD1OPRK1MAPK1 | |
| SCHEMBL21383790 | 0.79 | POLB (0.48) | POLBGPR119OPRD1OPRK1MAPK1 | |
| SCHEMBL31492730 | 0.79 | POLB (0.48) | POLBGPR119OPRD1OPRK1MAPK1 | |
| SCHEMBL21384217 | 0.79 | POLB (0.48) | POLBGPR119OPRD1OPRK1MAPK1 | |
| SCHEMBL30484944 | 0.79 | POLB (0.48) | POLBGPR119OPRD1OPRK1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020210384-A1 | PYRIMIDINONE DERIVATIVES AS SHP2 ANTAGONISTS | MERCK PATENT GMBH (DE) | 2020-10-15 | — | — | WO | disclosed |
| US-8883816-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883816-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20140045875-A1 | Fused and Spirocycle Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045875-A1 | Fused and Spirocycle Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8546417-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546417-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120309778-A1 | Fused and Spirocycle Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309778-A1 | Fused and Spirocycle Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2012-12-06 | — | — | US | disclosed |
| US-8193208-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193208-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20090118319-A1 | Fused and Spirocycle Compounds and the Use Thereof | EURO-CELTIQUE S.A. (LU) | 2009-05-07 | — | — | US | disclosed |
| US-20090118319-A1 | Fused and Spirocycle Compounds and the Use Thereof | EURO-CELTIQUE S.A. (LU) | 2009-05-07 | — | — | US | disclosed |
| WO-2007028638-A1 | FUSED AND SPIROCYCLE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309778-A1 | Fused and Spirocycle Compounds and the Use Thereof | CACNA1A, CACNA1E, CACNA1C | POLB 4722/4885GPR119 1357/4885OPRD1 123/4885 |
| US-20090118319-A1 | Fused and Spirocycle Compounds and the Use Thereof | CACNA1A, CACNA1E, CACNA1C | POLB 4722/4885GPR119 1357/4885OPRD1 123/4885 |
| US-20140045875-A1 | Fused and Spirocycle Compounds and the Use Thereof | CACNA1A, CACNA1E, CACNA1C | POLB 4722/4885GPR119 1357/4885OPRD1 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.